Recruiting
Phase 1
Phase 2

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Sponsor:

Loxo Oncology, Inc.

Code:

NCT03899792

Conditions

Medullary Thyroid Cancer

Infantile Myofibromatosis

Infantile Fibrosarcoma

Papillary Thyroid Cancer

Soft Tissue Sarcoma

Eligibility Criteria

Sex: All

Age: 6 - 21

Healthy Volunteers: Not accepted

Interventions

LOXO-292

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information